Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Portfolio Pulse from Lara Goldstein
The American Psychedelic Practitioners Association and BrainFutures have published the first-ever professional practice guidelines for psychedelic-assisted therapy. Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has finalized its clinical trial design for a phase 2 DMT stroke study. Atai Life Sciences, MindMed, and COMPASS Pathways have reported their Q2 2023 financial results. AdvisorShares Psychedelics ETF has seen a decrease in its weekly performance.
August 14, 2023 | 1:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Algernon Pharmaceuticals has finalized its clinical trial design for a phase 2 DMT stroke study.
The finalization of the clinical trial design for a phase 2 DMT stroke study could potentially lead to positive outcomes for the company, thus potentially increasing its stock value.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Atai Life Sciences reported its financial results for the second quarter 2023.
The reporting of Q2 2023 financial results by Atai Life Sciences is a routine disclosure and does not necessarily indicate a change in the company's stock value.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
AdvisorShares Psychedelics ETF has seen a decrease in its weekly performance.
The decrease in the weekly performance of AdvisorShares Psychedelics ETF could potentially lead to a decrease in its stock value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100